	US 11,945,882 B2
	Method for producing antibody-drug conjugate
Tatsuya Yamaguchi, Tokyo (JP); Takashi Kouko, Tokyo (JP); Shigeru Noguchi, Tokyo (JP); Yohei Yamane, Tokyo (JP); Fumikatsu Kondo, Tokyo (JP); Takahiro Aoki, Tokyo (JP); Tadahiro Takeda, Tokyo (JP); Kohei Sakanishi, Tokyo (JP); Hitoshi Sato, Tokyo (JP); Tsuyoshi Ueda, Tokyo (JP); Shinji Matuura, Tokyo (JP); Kei Kurahashi, Tokyo (JP); Yutaka Kitagawa, Tokyo (JP); and Tatsuya Nakamura, Tokyo (JP)
Assigned to DAIICHI SANKYO COMPANY, LIMITED, Tokyo (JP)
Appl. No. 16/642,245
Filed by DAIICHI SANKYO COMPANY, LIMITED, Tokyo (JP)
PCT Filed Aug. 30, 2018, PCT No. PCT/JP2018/032056 § 371(c)(1), (2) Date Feb. 26, 2020, PCT Pub. No. WO2019/044947, PCT Pub. Date Mar. 7, 2019.
Claims priority of application No. 2017-167691 (JP), filed on Aug. 31, 2017.
Prior Publication US 2020/0385422 A1, Dec. 10, 2020
Int. Cl. C07K 1/30 (2006.01); C07K 5/10 (2006.01)

CPC C07K 5/10 (2013.01) [C07B 2200/13 (2013.01)]

63 Claims

1. Crystals of the compound represented by formula (1):